Evaluation of Combined Biomarkers for Tumor Response to Immunotherapy (I/O) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Ramdani, H. [1 ]
Falk, M. [2 ]
Schatz, S. [2 ]
Tiemann, M. [2 ]
Heukamp, L. [2 ]
Schuuring, E. [3 ]
Groen, H. [3 ]
Griesinger, F. [4 ]
机构：
[1] Carl Von Ossietzky Univ Oldenburg, Innere Med Onkol, Oldenburg, Germany
[2] Hamatopathol Hamburg, Hamburg, Germany
[3] Univ Med Ctr Groningen, Groningen, Netherlands
[4] Carl von Ossietzky Univ Oldenburg, Pius Hosp, Dept Hematol & Oncol, Med Campus, Oldenburg, Germany
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
NSCLC; Immune Checkpoint Inhibitors; tumor mutational burden;
D O I：
10.1016/j.jtho.2019.08.1568
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.04-63
引用
收藏
页码：S732 / S733
页数：2
相关论文
共 50 条
  • [1] Evaluation of Combined Biomarkers for Tumor Response to Immunotherapy (I/O) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Ratnclani, Hayat
    Falk, Markus
    Schatz, Stefanie
    Heukamp, Lukas C.
    Tietnann, Markus
    Schuuring, Ed
    Groen, Harry
    Griesinger, Frank
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 121 - 121
  • [2] Evaluation of combined biomarkers for tumor response to immunotherapy (I/O) in patients with advanced non-small cell lung cancer (NSCLC)
    Ramdani, H.
    Falk, M.
    Schatz, S.
    Heukamp, L. C.
    Tiemann, M.
    Schuuring, E.
    Groen, H.
    Griesinger, F.
    PNEUMOLOGIE, 2020, 74 : S127 - S128
  • [3] Evaluation of combined biomarkers for tumor response to immunotherapy (I/O) in patients with advanced non-small cell lung cancer (NSCLC)
    Ramdani, H.
    Falk, M.
    Schatz, S.
    Tiemann, M.
    Heukamp, L. C.
    Schuuring, E.
    Groen, H. J.
    Griesinger, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 77 - 77
  • [4] Evaluation of combined biomarkers for tumor response to immunotherapy (I/O) in patients with advanced non-small cell lung cancer (NSCLC).
    Ramdani, Hayat Oum El Kheir
    Falk, Markus
    Schatz, Stefanie
    Tiemann, Markus
    Heukamp, Lukas
    Schuuring, Ed
    Groen, Harry J. M.
    Griesinger, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Evaluation of combined biomarker in response to immunotherapy (I/O) in patients with advanced non-small cell lung cancer (NSCLC)
    Ramdani, H. O.
    Shatz, S.
    Falk, M.
    Heukamp, L. C.
    Tiemann, M.
    Wesseler, C.
    Schuuring, E.
    Groen, H. J.
    Griesinger, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 153 - 153
  • [6] Evaluation of Combined Biomarker of Response to Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer
    Ramdani, H.
    Falk, M.
    Schatz, S.
    Heukamp, L.
    Tiemann, M.
    Wesseler, C.
    Schuuring, E.
    Groen, H.
    Griesinger, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S413 - S414
  • [7] Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review
    Indini, Alice
    Rijavec, Erika
    Grossi, Francesco
    CANCERS, 2021, 13 (08)
  • [8] EVALUATION OF BIOMARKERS IN PATIENTS WITH NON-SMALL CELL LUNG-CANCER (NSCLC)
    FOEMMEL, RS
    ALEXANDER, NA
    HIRSHAUT, Y
    KATOPODIS, N
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 182 - 182
  • [9] Clinical Predictive Markers of Response to Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC)
    Rhone, R.
    Raez, L.
    Dumais, K.
    Powery, H.
    Gentile, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1083 - S1083
  • [10] Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)
    Tsiara, Anna
    Liontos, Michalis
    Kaparelou, Maria
    Zakopoulou, Roubini
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
12345